EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Prognostic Significance of Peripheral Blood Parameters as Predictor of Neoadjuvant Chemotherapy Response in Breast Cancer

Ionut Flaviu Faur iD, Amadeus Dobrescu iD, Ioana Adelina Clim, Paul Pasca, Cosmin Burta, Cristi Tarta iD, Dan Brebu, Andreea-Adriana Neamtu iD, Vlad Braicu, Ciprian Duta, Bogdan Totolici

International Journal of Molecular Sciences · 12.03.2025 · 26 (6) · 2541

DOI: 10.3390/ijms26062541 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 12.03.2025. Verfasst von Ionut Flaviu Faur und 10 weiteren Autor:innen. Beteiligte Einrichtung: IInd Surgery Clinic, Timisoara Emergency County Hospital, 300723 Timisoara, Romania. Hauptthemen laut MEDLINE: Breast Neoplasms, Neoadjuvant Therapy. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Victor Babes University of Medicine and Pharmacy Timisoara.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The standard treatment for breast cancer typically includes surgery, often followed by systemic therapy and individualized treatment regimens. However, there is growing interest in identifying pre-therapeutic biomarkers that can predict tumor response to neoadjuvant chemotherapy (NACT). This study systematically evaluated various analytical parameters, including age, TNM stage, histological type, molecular subtype, and several biomarker ratios, such as the platelet-to-lymphocyte ratio (PLR), neutrophil-to-lymphocyte ratio (NLR), lymphocyte-to-monocyte ratio (LMR), systemic immune-inflammatory index (SII), and prognostic nutritional index (PNI). We aimed to assess the predictive value of these parameters regarding the tumor’s response rate to NACT. The analysis revealed a statistically significant association between the pathological complete response—pCR (absence of any detectable cancer cells in the tissue following neoadjuvant chemotherapy (NACT))—rate and NLR in the subgroup with values between 1 and 3 (p = 0.001). The optimal cut-off for PLR was determined to be 120.45, with 80.55% of patients achieving pCR showing PLR values below this threshold (p = 0.000). Similarly, the LMR cut-off was found to be 12.34, with 77.77% of patients with pCR having LMR values below this threshold (p = 0.002). Additionally, lower pre-therapeutic values of NLR (p < 0.001), PLR (p = 0.002), SII (p = 0.001), and LMR (p = 0.001) were significantly correlated with pCR compared to the non-pCR subgroup (p < 0.005). These findings highlight the predictive potential of these biomarkers for achieving pCR following NACT. Our study supports the hypothesis that pre-therapeutic values of NLR, PLR, SII, and LMR can serve as predictive biomarkers for pCR in breast cancer patients undergoing NACT. However, the PNI did not demonstrate predictive potential in relation to pCR. These biomarkers may provide valuable insights into patient prognosis and guide personalized treatment strategies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Breast NeoplasmsNeoadjuvant TherapyHumansFemaleMiddle AgedPrognosisAdultAgedNeutrophilsBiomarkers, TumorLymphocytesChemotherapy, AdjuvantBlood PlateletsTreatment Outcome

Stichwörter der Autor:innen

neutrophil-to-lymphocyte ratio (NLR)pathological complete response (pCR)platelet-to-lymphocyte ratio (PLR)systemic immune-inflammatory index (SII)

Substanzen

Biomarkers, Tumor

Autor:innen und Institutionen

  • IInd Surgery Clinic, Timisoara Emergency County Hospital, 300723 Timisoara, Romania.
  • X Department of General Surgery, "Victor Babes" University of Medicine and Pharmacy Timisoara, Eftimie Murgu Square 2, 300041 Timisoara, Romania.
  • Multidisciplinary Doctoral School "Vasile Goldiș", Western University of Arad, 310025 Arad, Romania.
  • Doctoral School of Medicine, "Victor Babes" University of Medicine and Pharmacy Timisoara, Eftimie Murgu Square 2, 300041 Timisoara, Romania.
  • Faculty of Medicine, "Victor Babes" University of Medicine and Pharmacy Timisoara, Eftimie Murgu Square 2, 300041 Timisoara, Romania.
  • Faculty of Pharmacy, "Victor Babes" University of Medicine and Pharmacy Timisoara, Eftimie Murgu Square 2, 300041 Timisoara, Romania.

ORCID-Profile: Ionut Flaviu Faur, Amadeus Dobrescu, Cristi Tarta, Andreea-Adriana Neamtu

Förderung

  • Victor Babes University of Medicine and Pharmacy Timisoara

Zitieren

APA

Faur, I. F., Dobrescu, A., Clim, I. A., Pasca, P., Burta, C., Tarta, C., Brebu, D., Neamtu, A. A., Braicu, V., Duta, C., & Totolici, B. (2025). Prognostic Significance of Peripheral Blood Parameters as Predictor of Neoadjuvant Chemotherapy Response in Breast Cancer. International Journal of Molecular Sciences, 26(6), 2541. https://doi.org/10.3390/ijms26062541

Vancouver

Faur IF, Dobrescu A, Clim IA, Pasca P, Burta C, Tarta C, et al. Prognostic Significance of Peripheral Blood Parameters as Predictor of Neoadjuvant Chemotherapy Response in Breast Cancer. International Journal of Molecular Sciences. 2025;26(6):2541. doi:10.3390/ijms26062541

BibTeX
@article{Faur2025,
  author = {Faur, Ionut Flaviu and Dobrescu, Amadeus and Clim, Ioana Adelina and Pasca, Paul and Burta, Cosmin and Tarta, Cristi and Brebu, Dan and Neamtu, Andreea-Adriana and Braicu, Vlad and Duta, Ciprian and Totolici, Bogdan},
  title = {Prognostic Significance of Peripheral Blood Parameters as Predictor of Neoadjuvant Chemotherapy Response in Breast Cancer},
  journal = {International Journal of Molecular Sciences},
  year = {2025},
  volume = {26},
  number = {6},
  pages = {2541},
  doi = {10.3390/ijms26062541}
}
Kostenlos starten →